Plasma cell dedifferentiation in refractory multiple myeloma

Br J Haematol. 2021 Apr;193(2):212. doi: 10.1111/bjh.17244. Epub 2021 Mar 26.

Authors

Ahmadreza Arbab¹, Veronique Saada², Sophie Cotteret³, Christophe Marzac⁴, David Ghez²

Affiliations

¹ Gustave Roussy Institute, Villejuif, France.
² Hematology, Gustave Roussy Cancer Center, Villejuif, France.
³ Biology-Pathology Department, Gustave Roussy Cancer Center, Villejuif, France.
⁴ Biology-Pathology, Gustave Roussy Cancer Center, Villejuif, France.

PMID: 33772753
DOI: 10.1111/bjh.17244

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Cell Dedifferentiation / drug effects*
Cell Dedifferentiation / physiology
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Dexamethasone / therapeutic use
Flow Cytometry / methods
Humans
Immunophenotyping / methods
Male
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Mutation
Myelodysplastic Syndromes / chemically induced
Paraproteinemias / blood*
Plasma Cells / pathology*
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use
Treatment Failure
Tumor Suppressor Protein p53 / genetics

Substances

Antibodies, Monoclonal
TP53 protein, human
Tumor Suppressor Protein p53
daratumumab
Thalidomide
Dexamethasone
pomalidomide